1-(2-mercaptopropyl)-4-methylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2-mercaptopropyl)-4-methylpiperazine
• 英文别名: 1-(4-methylpiperazin-1-yl)propane-2-thiol
• 化学式: C₈H₁₈N₂S
• 分子量: 174.31
• InChiKey: NICHLBUXOSZKHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  7.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  硫化丙烯 、 N-甲基哌嗪 在 oil 作用下， 100.0~105.0 ℃ 、173.32 kPa 条件下， 反应 16.0h， 生成 1-(2-mercaptopropyl)-4-methylpiperazine
  参考文献：
  名称：

  Pristinamycin II.sub.B derivatives and compositions containing them

  摘要：

  Pristinamycin II.sub.B 衍生物的公式为：##STR1## 其中 R 表示一种含氮的4至7元杂环环，该环可以选择性地被烷基取代；或烷基（2至4个碳原子）被1或2个苯基、环烷基氨基或N-烷基-N-环烷基氨基（3至6个环原子）、烷基氨基、二烷基氨基或二烷基氨基甲酰氧基基团取代（这2个后者的二烷基氨基基团能够形成一个4至7元杂环环，该环可以选择性地被烷基取代），或被1或2个含氮的4至7元杂环环取代，这些环可以选择性地被烷基取代，上述取代基中至少有一个是能够形成盐的含氮取代基，n为1或2，所有烷基均为线性或支链烷基，含（除非另有说明）1至10个碳原子，它们的异构体、盐和制备方法。这些化合物，可以与已知的协同素或协同素的公式：##STR2## 以及它们的组合物一起作为抗微生物剂使用。

  公开号：

  US04668669A1

文献信息

• Pristinamycin derivatives, their preparation and their use
  申请人：Rhone-Poulenc Sante

  公开号：US04590004A1

  公开（公告）日：1986-05-20

  The invention provides new pristinamycin II.sub.B derivatives of the formula: ##STR1## in which R represents alkylthio substituted by (i) alkylamino or dialkylamino of which the alkyl parts can form a pyrrolidin-1-yl, piperidino, azetidin-1-yl, azepin-1-yl, morpholino, thiomorpholino or piperazin-1-yl ring (optionally substituted by alkyl), or (ii) pyrrolidin-2-yl or pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl or piperidin-4-yl, azetidin-2-yl or azetidin-3-yl or azepin-2-yl, azepin-3-yl or azepin-4-yl; a radical Het-S-, in which Het is pyrrolidin-3-yl, piperidin-3-yl or piperidin-4-yl, azetidin-3-yl or azepin-3-yl or azepin-4-yl optionally N-alkylsubstituted; or dialkylamino of which the alkyl parts can form a pyrrolidin-1-yl, piperidino, azetidin-1-yl, azepin-1-yl, morpholino, thiomorpholino or piperazin-1-yl ring (optionally substituted by alkyl), the said alkyls having 1 to 5 carbon atoms each in a linear or branched chain. The compounds of the formula (I) are useful as antimicrobial agents when used in association with known synergistines or synergistines of the formula: ##STR2##

  本发明提供了新的pristinamycin II.sub.B衍生物，其化学式为：##STR1## 其中R代表烷基硫代基，该烷基硫代基被(i)烷基氨基或二烷基氨基取代，其中烷基部分可以形成吡咯烷-1-基，哌啶基，氮杂环丙烷-1-基，氮杂环庚烷-1-基，吗啉基，硫代吗啉基或哌嗪-1-基环（可选地被烷基取代），或(ii)吡咯烷-2-基或吡咯烷-3-基，哌啶-2-基，哌啶-3-基或哌啶-4-基，氮杂环丙烷-2-基或氮杂环丙烷-3-基或氮杂环庚烷-2-基，氮杂环庚烷-3-基或氮杂环庚烷-4-基；一个基团Het-S-，其中Het是吡咯烷-3-基，哌啶-3-基或哌啶-4-基，氮杂环丙烷-3-基或氮杂环庚烷-3-基或氮杂环庚烷-4-基，可选地被N-烷基取代；或二烷基氨基，其中烷基部分可以形成吡咯烷-1-基，哌啶基，氮杂环丙烷-1-基，氮杂环庚烷-1-基，吗啉基，硫代吗啉基或哌嗪-1-基环（可选地被烷基取代），所述的烷基具有1至5个碳原子，每个碳原子在直链或支链中。式（I）化合物在与已知的协同素或式的协同素一起使用时，可用作抗微生物剂。：##STR2##
• Synergistine derivatives and their preparation
  申请人：Rhone-Poulenc Sante

  公开号：US04617377A1

  公开（公告）日：1986-10-14

  The invention provides new synergistine derivatives of the formula: ##STR1## in which Y=H or N(CH.sub.3).sub.2 and R represents: (a) H or OH, (b) a radical of the formula NR.sub.1 R.sub.2, in which R.sub.1 and R.sub.2 =H, phenyl or pyridyl (optionally substituted by dialkylamino (1 to 4 C), alkyl (1 to 10 C) [optionally substituted by OH, SH, COOH, anilino, or alkylamino or dialkylamino of which at least one of the alkyl parts is substituted by OH, SH, COOH or anilino 9 , alkenyl (3 or 4 C) or alkynyl (3 or 4 C), or alternatively R.sub.1 and R.sub.2 together form a heterocycle optionally containing another heteroatom such as O, S or N (optionally substituted by alkyl), or (c) a halogen atom, a trimethylsilyloxy or dialkylphosphoryloxy radical or a radical --OSO.sub.2 R.sub.3 or --OCOR.sub.4, R.sub.3 being alkyl, trifluoromethyl, trichloromethyl or optionally substituted phenyl and R.sub.4 being defined in the same way as R.sub.3 or being an acylalkyl, alkoxycarbonylalkyl or alkoxy radical, and also their salts and their preparation. These products are useful as intermediates in the synthesis of anti-bacterial synergistine derivatives.

  本发明提供了新的协同素衍生物，其化学式为：## STR1 ## 其中Y = H或N（CH.sub.3）.sub.2，R代表：（a）H或OH，（b）式NR.sub.1R.sub.2的基团，其中R.sub.1和R.sub.2 = H，苯基或吡啶基（可选地被二烷基氨基（1至4 C），烷基（1至10 C）[可选地被OH，SH，COOH，苯胺基，或烷基氨基或二烷基氨基取代，其中至少有一个烷基部分被OH，SH，COOH或苯胺基9取代，烯基（3或4 C）或炔基（3或4 C），或者R.sub.1和R.sub.2一起形成一个杂环，可选地含有另一个杂原子，例如O，S或N（可选地被烷基取代），或（c）卤原子，三甲基硅氧基或二烷基磷酰氧基基团或基团--OSO.sub.2R.sub.3或--OCOR.sub.4，其中R.sub.3为烷基，三氟甲基，三氯甲基或可选地取代的苯基，R.sub.4的定义与R.sub.3相同或为酰基烷基，烷氧羰基烷基或烷氧基基团，并且它们的盐及其制备方法。这些产品可用作合成抗菌协同素衍生物的中间体。
• Synergistine derivatives having anti-bacterial activity and their use
  申请人：Rhone-Poulenc Sante

  公开号：US04618599A1

  公开（公告）日：1986-10-21

  The invention provides new synergistine derivatives of the formula: ##STR1## in which Y=H or N(CH.sub.3).sub.2 and (a) R.sub.1 and R.sub.2 =H and R=pyrrolidin-3-ylthio or piperidin-3-ylthio or piperidin-4-ylthio (optionally substituted by alkyl), or altenatively R=alkylthio substituted by 1 or 2 SO.sub.3 H radicals or alkylamino or dialkylamino radicals (optionally substituted) or by 1 or 2 piperazino rings (optionally substituted) or morpholino, thiomorpholino, piperidino, pyrrolidin-1-yl, piperidin-2-yl, piperidin-3-yl or piperidin-4-yl or pyrrolidin-2-yl or pyrrolidin-3-yl rings (these last 5 rings being optionally substituted by alkyl), or (b) R.sub.1 and R.sub.2 form a bond and R=pyrrolidin-3-ylamino, piperidin-3-ylamino or piperidin-4-ylamino, pyrrolidin-3-yloxy, piperidin-3-yloxy or piperidin-4-yloxy, pyrrolidin-3-ylthio, piperidin-3-ylthio or piperidin-4-ylthio (optionally substituted by alkyl), or alternatively R=alkylamino, alkoxy or alkylthio substituted by 1 or 2 SO.sub.3 H radicals, alkylamino or dialkylamino radicals (optionally substituted) or trialkylammonio or imidazol-4-yl or imidazol-5-yl radicals or by 1 or 2 piperazino rings (optionally substituted by alkyl) or morpholino, thiomorpholino, piperidino, pyrrolidin-1-yl, piperidin-2-yl, piperidin-3-yl or piperidin-4-yl or pyrrolidin-2-yl or pyrrolidin-3-yl rings (these last two rings being optionally substituted by alkyl), and their salts, their preparation, and the pharmaceutical compositions in which they are present. These compounds are useful as anitbacterial agents.

  本发明提供了新的协同素衍生物，其化学式为：##STR1## 其中Y=H或N(CH.sub.3).sub.2，且（a）R.sub.1和R.sub.2=H，R=吡咯烷-3-基硫或哌啶-3-基硫或哌啶-4-基硫（可选地被烷基取代），或者替代的R=1或2个SO.sub.3H基团或烷基氨基或二烷基氨基基团（可选地被取代）或1或2个哌嗪环（可选地被取代）或吗啡环、硫代吗啡环、哌啶环、吡咯烷-1-基、哌啶-2-基、哌啶-3-基或哌啶-4-基或吡咯烷-2-基或吡咯烷-3-基环（这些最后5个环可选地被烷基取代），或（b）R.sub.1和R.sub.2形成键，R=吡咯烷-3-基氨基、哌啶-3-基氨基或哌啶-4-基氨基、吡咯烷-3-氧基、哌啶-3-氧基或哌啶-4-氧基、吡咯烷-3-基硫或哌啶-3-基硫或哌啶-4-基硫（可选地被烷基取代），或者替代的R=烷基氨基、烷氧基或烷基硫基，其上带有1或2个SO.sub.3H基团、烷基氨基或二烷基氨基基团（可选地被取代）或三烷基铵或咪唑-4-基或咪唑-5-基基团或1或2个哌嗪环（可选地被烷基取代）或吗啡环、硫代吗啡环、哌啶环、吡咯烷-1-基、哌啶-2-基、哌啶-3-基或哌啶-4-基或吡咯烷-2-基或吡咯烷-3-基环（这两个最后的环可选地被烷基取代），以及它们的盐、制备方法和制剂。这些化合物可用作抗菌剂。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3798214A1

  公开（公告）日：2021-03-31

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明的特征是一种式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、W、X、Y、Z、n、o、p 和 q 在本文中定义，用于治疗 CFTR 介导的疾病，如囊性纤维化。本发明还包括药物组合物、治疗方法及其试剂盒。
• Imidazolyl kinase inhibitors and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10975058B2

  公开（公告）日：2021-04-13

  The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

  本公开提供了式(I)的咪唑化合物和制备该化合物的方法。所提供的化合物能够与蛋白激酶结合，可用于调节（如抑制）受试者或细胞中蛋白激酶的活性，和/或治疗或预防有需要的受试者的疾病（如增殖性疾病、遗传性疾病、血液病、神经性疾病、疼痛性疾病、精神疾病或代谢性疾病）。还提供了包括或涉及本文所述化合物的药物组合物、试剂盒、方法和用途。